Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THOR: Pembrolizumab and Olaparib in ES-SCLC
NCT05623319Phase 2Recruiting
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Mar 2023
- Primary completion
- Jul 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, olaparib in small cell lung cancer (SCLC), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Started Mar 2023; status: recruiting.
02
Drugs
pembrolizumabolaparib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05623319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05623319.